379 related articles for article (PubMed ID: 25175600)
81. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
Sun Y; Estevez A; Schlothauer T; Wecksler AT
MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
[TBL] [Abstract][Full Text] [Related]
82. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
83. C-terminal lysine clipping of IgG1: impact on binding to human FcγRIIIa and neonatal Fc receptors.
Faid V; Leblanc Y; Berger M; Seifert A; Bihoreau N; Chevreux G
Eur J Pharm Sci; 2021 Apr; 159():105730. PubMed ID: 33493670
[TBL] [Abstract][Full Text] [Related]
84. X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.
Mezo AR; Sridhar V; Badger J; Sakorafas P; Nienaber V
J Biol Chem; 2010 Sep; 285(36):27694-701. PubMed ID: 20592032
[TBL] [Abstract][Full Text] [Related]
85. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn.
Ying T; Wang Y; Feng Y; Prabakaran P; Gong R; Wang L; Crowder K; Dimitrov DS
MAbs; 2015; 7(5):922-30. PubMed ID: 26179052
[TBL] [Abstract][Full Text] [Related]
86. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
87. Extending human IgG half-life using structure-guided design.
Booth BJ; Ramakrishnan B; Narayan K; Wollacott AM; Babcock GJ; Shriver Z; Viswanathan K
MAbs; 2018 Oct; 10(7):1098-1110. PubMed ID: 29947573
[TBL] [Abstract][Full Text] [Related]
88. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
Reusch J; Andersen JT; Rant U; Schlothauer T
MAbs; 2024; 16(1):2361585. PubMed ID: 38849969
[TBL] [Abstract][Full Text] [Related]
89. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement.
Brinkhaus M; Pannecoucke E; van der Kooi EJ; Bentlage AEH; Derksen NIL; Andries J; Balbino B; Sips M; Ulrichts P; Verheesen P; de Haard H; Rispens T; Savvides SN; Vidarsson G
Nat Commun; 2022 Oct; 13(1):6073. PubMed ID: 36241613
[TBL] [Abstract][Full Text] [Related]
90. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
[TBL] [Abstract][Full Text] [Related]
91. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
Andersen JT; Daba MB; Sandlie I
Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
[TBL] [Abstract][Full Text] [Related]
92. Neonatal Fc receptor and IgG-based therapeutics.
Kuo TT; Aveson VG
MAbs; 2011; 3(5):422-30. PubMed ID: 22048693
[TBL] [Abstract][Full Text] [Related]
93. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
94. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
95. Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody.
Kenniston JA; Taylor BM; Conley GP; Cosic J; Kopacz KJ; Lindberg AP; Comeau SR; Atkins K; Bullen J; TenHoor C; Adelman BA; Sexton DJ; Edwards TE; Nixon AE
J Biol Chem; 2017 Oct; 292(42):17449-17460. PubMed ID: 28878017
[TBL] [Abstract][Full Text] [Related]
96. Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge.
Stapleton NM; Brinkhaus M; Armour KL; Bentlage AEH; de Taeye SW; Temming AR; Mok JY; Brasser G; Maas M; van Esch WJE; Clark MR; Williamson LM; van der Schoot CE; Vidarsson G
Sci Rep; 2019 May; 9(1):7363. PubMed ID: 31089170
[TBL] [Abstract][Full Text] [Related]
97. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1.
Medesan C; Matesoi D; Radu C; Ghetie V; Ward ES
J Immunol; 1997 Mar; 158(5):2211-7. PubMed ID: 9036967
[TBL] [Abstract][Full Text] [Related]
98. Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris.
Lee CH; Choi DK; Choi HJ; Song MY; Kim YS
Protein Expr Purif; 2010 May; 71(1):42-8. PubMed ID: 20006709
[TBL] [Abstract][Full Text] [Related]
99. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
100. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
